KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) Enterprise Value (2016 - 2025)

Resmed's Enterprise Value history spans 17 years, with the latest figure at -$1.4 billion for Q4 2025.

  • For Q4 2025, Enterprise Value fell 171.5% year-over-year to -$1.4 billion; the TTM value through Dec 2025 reached -$1.4 billion, down 171.5%, while the annual FY2025 figure was -$1.2 billion, 407.4% down from the prior year.
  • Enterprise Value reached -$1.4 billion in Q4 2025 per RMD's latest filing, down from -$1.4 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$194.5 million in Q4 2021 to a low of -$1.4 billion in Q4 2025.
  • Average Enterprise Value over 5 years is -$458.8 million, with a median of -$245.8 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: soared 36.25% in 2021, then crashed 407.4% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$194.5 million in 2021, then crashed by 30.2% to -$253.2 million in 2022, then rose by 16.96% to -$210.2 million in 2023, then crashed by 148.25% to -$521.9 million in 2024, then plummeted by 171.5% to -$1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RMD's Enterprise Value are -$1.4 billion (Q4 2025), -$1.4 billion (Q3 2025), and -$1.2 billion (Q2 2025).